Evidence map›Paper›PMID 38918372›Full record

ArticleBlood cancer journal2024

Are thrombosis, progression, and survival in ET predictable?

Ghaith Abu-Zeinah, Katie Erdos, Neville Lee, Ahamed Lebbe, Imane Bouhali, Mohammed Khalid, Richard T Silver, Joseph M Scandura

Abstract readLetter
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ghaith Abu-Zeinah *Richard T. Silver Myeloproliferative Neoplasms Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA. gfa2001@med.cornell.edu.ORCID 0000-0002-1881-3670
Katie Erdos *Richard T. Silver Myeloproliferative Neoplasms Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
Neville LeeRichard T. Silver Myeloproliferative Neoplasms Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.
Ahamed LebbeWeill Cornell Medicine-Qatar, Doha, Qatar.
Imane BouhaliWeill Cornell Medicine-Qatar, Doha, Qatar.
Mohammed KhalidWeill Cornell Medicine-Qatar, Doha, Qatar.
Richard T SilverRichard T. Silver Myeloproliferative Neoplasms Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8524-0964
Joseph M ScanduraRichard T. Silver Myeloproliferative Neoplasms Center, Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.

Funding

Clinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Disease ProgressionThrombosisAdultAgedFemaleHumansMaleMiddle AgedPrognosis

Identifiers

PMID38918372
PMCPMC11199579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.